Biogen (NASDAQ: BIIB) reported Q3 EPS of $6.31, $0.61 better than the analyst estimate of $5.70. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $3.03 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

Earnings Guidance Hot Earnings

Biogen (BIIB) PT Raised to $355 at Leerink PartnersOctober 25, 2017 7:29 AM Biogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple SclerosisOctober 25, 2017 5:56 AM BMO Capital Upgrades Biogen (BIIB) to OutperformOctober 25, 2017 1:01 AM SPINRAZA Confusion Creates a Buying Opportunity in Biogen (BIIB) - StifelOctober 24, 2017 11:58 AM Biogen Reports Quarterly Revenues of $3.1 BillionOctober 24, 2017 6:59 AM